Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Rijckborst V., Hansen B. E. , Ferenci P., Brunetto M. R. , Tabak F. , Cakaloglu Y., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.56, sa.5, ss.1006-1011, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Konu: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/j.jhep.2011.12.007
  • Sayfa Sayıları: ss.1006-1011


Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with <2 log hepatitis B virus (HBV) DNA decline at week 12 of a 48-week peginterferon alfa-2a (PEG-IFN) treatment course achieved a sustained response (SR). We aimed at validating this stopping rule in two independent trials.